z-logo
open-access-imgOpen Access
Intratracheal Administration of Recombinant Human Keratinocyte Growth Factor Promotes Alveolar Epithelial Cell Proliferation during Compensatory Lung Growth in Rat
Author(s) -
Katsuro Furukawa,
Keitaro Matsumoto,
Takeshi Nagayasu,
Tomomi YamamotoFukuda,
Shuichi Tobinaga,
Takafumi Abo,
Naoya Yamasaki,
Tomoshi Tsuchiya,
Takuro Miyazaki,
Ryotaro Kamohara,
Atsushi Nanashima,
Masayuki Obatake,
Takehiko Koji
Publication year - 2013
Publication title -
acta histochemica et cytochemica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.422
H-Index - 26
eISSN - 1347-5800
pISSN - 0044-5991
DOI - 10.1267/ahc.13036
Subject(s) - proliferating cell nuclear antigen , keratinocyte growth factor , lung , immunostaining , cell growth , terminal deoxynucleotidyl transferase , proliferation index , immunohistochemistry , andrology , growth factor , pathology , biology , chemistry , tunel assay , medicine , receptor , biochemistry
Keratinocyte growth factor (KGF) is considered to be one of the most important mitogens for lung epithelial cells. The objectives of this study were to confirm the effectiveness of intratracheal injection of recombinant human KGF (rhKGF) during compensatory lung growth and to optimize the instillation protocol. Here, trilobectomy in adult rat was performed, followed by intratracheal rhKGF instillation with low (0.4 mg/kg) and high (4 mg/kg) doses at various time-points. The proliferation of alveolar cells was assessed by the immunostaining for proliferating cell nuclear antigen (PCNA) in the residual lung. We also investigated other immunohistochemical parameters such as KGF, KGF receptor and surfactant protein A as well as terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Consequently, intratracheal single injection of rhKGF in high dose group significantly increased PCNA labeling index (LI) of alveolar cells in the remaining lung. Surprisingly, there was no difference in PCNA LI between low and high doses of rhKGF with daily injection, and PCNA LI reached a plateau level with 2 days-consecutive administration (about 60%). Our results indicate that even at low dose, daily intratracheal injection is effective to maintain high proliferative states during the early phase of compensatory lung growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom